Michael H. Tardugno
Chairman, President and Chief Executive Officer
Michael Tardugno’s career has been exclusively focused in healthcare, with 30 years of experience in the pharmaceutical and medical device industries. Mr. Tardugno was appointed President and Chief Executive Officer of Celsion on January 3, 2007 and was elected to the Board of Directors on January 22, 2007. Prior to joining the company, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories, where he held positions in pharmaceutical operations. Mr. Tardugno holds a B.S. in Biology from St. Bonaventure University and completed the Harvard Business School executive program.
Khursheed Anwer, Ph.D., M.B.A.
Executive Vice President and Chief Scientific Officer
Khursheed Anwer, Ph.D., M.B.A., assumed the title of Executive Vice President and Chief Scientific Officer, EGEN, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Scientific Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002 as Vice President of Research and Development, and directed the company’s clinical and research and development functions throughout his tenure at EGEN, Inc. Dr. Anwer has a Ph.D. in Physiology/Pharmacology from Ohio University and received post-doctoral training from the University of Texas Health Science Center at Houston. Before joining EGEN, Inc., Dr. Anwer was Director of Pre-Clinical Development at Valentis, Inc. From 1993 to 1999, he served in several positions at GeneMedicine, Inc., where he led several research projects in the area of non-viral gene therapy. He has authored more than 40 publications in the area of non-viral gene therapy, resulting from his active career in research and development. Dr. Anwer is an adjunct faculty member in the Biology Department at the University of Alabama in Huntsville and a board member of the University of Alabama Business School, STEP.
Nicholas Borys, M.D.
Senior Vice President and Chief Medical Officer
Nicholas Borys, M.D. joined Celsion in October 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in all phases of pharmaceutical development, with a focus in oncology. Prior to joining Celsion, he held increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an M.D. degree from American University of the Caribbean.
Jeffrey W. Church
Senior Vice President, Chief Financial Officer and Corporate Secretary
Jeffrey W. Church was appointed Senior Vice President and Chief Financial Officer of Celsion in July 2013. The appointment marked Mr. Church’s resumption of the role of Chief Financial Officer, a position he held prior to his promotion to Senior Vice President in July 2011, while also granting him responsibility for corporate investor relations. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. He brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining Celsion, Mr. Church held senior financial executive positions with several private and public clinical-stage life science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm Price Waterhouse. Mr. Church holds a B.S. degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.
Jason Fewell, Ph.D.
Vice President, Preclinical Research
Jason Fewell, Ph.D., assumed the title of Vice President, Preclinical Research at the time of Celsion’s acquisition of EGEN, Inc., where he held the position of Vice President, Preclinical Research and Development. He joined EGEN, Inc. in July, 2003 as Director of Biology. At EGEN, Dr. Fewell was involved in all aspects of the discovery and development of the company’s current clinical-stage gene therapy product, as well as the pre-clinical development of EGEN’s RNA interference (RNAi) platform technologies. Prior to EGEN, Dr. Fewell was a Senior Scientist at Valentis, Inc., where he led pre-clinical research projects in the area of non-viral gene therapy for the treatment of hemophilia B and hepatitis C infection. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at the Children’s Hospital Medical Center at Cincinnati, Ohio, in the department of Molecular Cardiovascular Biology. Dr. Fewell has an extensive publication history in his field and is a named inventor on numerous patents and patent applications.